Dr. Gregory M. Fuller, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 269
Licensed in Texas since 1990, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Arkansas College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license H8646 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- North Hills Family Practice, PA (5 clinicians)
- Southlake Wound Care and Hyperbarics (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 269
- Services billed
- 9,307
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 283 | 148 |
| Established patient office or other outpatient visit, 30-39 minutes | 272 | 156 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 73 | 73 |
| Assessment of emotional or behavioral problems | 47 | 47 |
| Automated urinalysis test | 36 | 21 |
| Detection test by immunoassay with direct visual observation for influenza virus | 30 | 13 |
| Annual depression screening, 5 to 15 minutes | 28 | 28 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 22 | 18 |
| X-ray of chest, 2 views | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 72 payments worth $3,468 in total to this clinician.
| Shionogi Inc | $1,820 |
|---|---|
| Pfizer Inc. | $287 |
| GlaxoSmithKline, LLC. | $182 |
| AstraZeneca Pharmaceuticals LP | $167 |
| Novo Nordisk Inc | $146 |
| Lilly USA, LLC | $129 |
| Dexcom, Inc. | $122 |
| Phathom Pharmaceuticals, Inc. | $98.14 |
| Consulting Fee | $1,820 |
|---|---|
| Food and Beverage | $1,648 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Shionogi Inc Oct 27, 2025 | Consulting Fee S-217622 · Infections and Infectious Diseases | $1,820 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $549,453 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - Roche Cancer Screening Collection Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.